PDK1 and ovarian carcinoma: This finding is consistent with our previous investigation (Park et al., 2015) and a study by other researchers using the PDK1 inhibitor 2-O-Bn-InsP5, which also inhibited both T308 and S473 phosphorylation in the SKOV-3 ovarian cancer cell line (Falasca et al., 2010).